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Abstract
Purpose—A major factor limiting the effective clinical management of colorectal cancer (CRC)
is resistance to chemotherapy. Therefore, the identification of novel, therapeutically targetable
mediators of resistance is vital.
Experimental design—We used a CRC disease-focused microarray platform to
transcriptionally profile chemotherapy-responsive and non-responsive pre-treatment metastatic
CRC liver biopsies and in vitro samples, both sensitive and resistant to clinically relevant
chemotherapeutic drugs (5-FU and oxaliplatin). Pathway and gene set enrichment analyses
(GSEA) identified candidate genes within key pathways mediating drug resistance. Functional
RNAi screening identified regulators of drug resistance.
Results—MAPK signalling, focal adhesion, cell cycle, insulin signalling and apoptosis were
identified as key pathways involved in mediating drug resistance. The G-protein coupled receptor
galanin receptor 1 (GalR1) was identified as a novel regulator of drug resistance. Notably,
silencing either GalR1 or its ligand galanin, induced apoptosis in drug-sensitive and resistant cell
lines and synergistically enhanced the effects of chemotherapy. Mechanistically, GalR1/galanin
silencing resulted in down-regulation of the endogenous caspase 8 inhibitor FLIPL, resulting in
induction of caspase 8-dependent apoptosis. Galanin mRNA was found to be overexpressed in
colorectal tumours, and importantly, high galanin expression correlated with poor disease-free
survival of early stage CRC patients.
Conclusion—This study demonstrates the power of systems biology approaches to identify key
pathways and genes that are functionally involved in mediating chemotherapy resistance.
Moreover, we have identified a novel role for the GalR1/galanin receptor-ligand axis in chemo-
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resistance, providing evidence to support its further evaluation as a potential therapeutic target and
biomarker in CRC.
INTRODUCTION
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in Europe and
North America. 5-Fluorouracil (5-FU)-based chemotherapy regimens remain the standard
treatment for CRC in both the adjuvant and advanced disease settings. However, response
rates to 5-FU therapy are between 10-20% in the metastatic setting (1). Combining 5-FU
with the DNA-damaging agent oxaliplatin has significantly improved response rates for
advanced colorectal cancer to 40-50%, however 5 year overall survival remains less than 5%
(2). Resistance to chemotherapy, either intrinsic or acquired, ultimately results in treatment
failure for the vast majority of patients with metastatic disease and also is a major problem
in the locally advanced disease setting, where 40-50% patients relapse (3).Therefore, novel
therapeutic strategies are urgently required.
The anti-cancer activities of 5-FU include thymidylate synthase (TS) inhibition and
incorporation of its metabolites into RNA and DNA (4). Known determinants of 5-FU
response include expression levels of TS and the 5-FU catabolic enzyme dihydropyrimidine
dehydrogenase (DPD) which mediates the degradation of 5-FU (4). Oxaliplatin is a third
generation platinum compound which forms platinum-DNA adducts leading to cytotoxicity.
Known determinants of response include expression of excision repair cross-complementing
1 protein (ERCC1) and xeroderma pigmentosum group A (XPA). These are central
components of the nucleotide excision repair (NER) pathway, which is the major repair
pathway of platinum drug-induced DNA damage (5). Despite our understanding of many of
the pathways that regulate 5-FU- and oxaliplatin-induced cell death and the mechanisms by
which resistance to these chemotherapeutic agents arises, this knowledge has failed to
translate to clinical practice. There is, therefore, an urgency to identify novel mediators of 5-
FU/oxaliplatin resistance that are “druggable” and/or useful predictive biomarkers of clinical
response.
In the present study, we used a systems biology approach incorporating microarray profiling
of clinical and in vitro samples, bioinformatic analyses and functional RNAi screens to
identify novel mediators of resistance to 5-FU and oxaliplatin. Our group has previously
used gene expression profiles derived from cell line models of known drug sensitivity to
generate classifiers that predict clinical response to 5-FU/SN-38 therapy (6). This type of
approach also provides novel mechanistic insights into how drug resistance arises. RNAi has
proved to be a powerful tool in the identification of genes that are synthetically lethal with
oncogenes such as Kras (7), and genes that impact on drug sensitivity in vitro (8). In the
present study, we identified the mitogen-activated protein kinase (MAPK) signaling, focal
adhesion, cell cycle, insulin signaling and apoptosis pathways as important regulators of
chemo-resistance in CRC. In particular, for the first time we report the stem cell marker and
regulator, galanin (9-14), and its receptor the G-protein coupled receptor galanin receptor 1
(GalR1) as key determinants of drug resistance and potential therapeutic targets for
combating drug resistance. Mechanistically, we identify a novel role for the GalR1/galanin
receptor-ligand axis as an important upstream regulator of expression of the anti-apoptotic
protein FLIPL. Clinically, galanin mRNA was found to be overexpressed in colorectal
tumours, and notably, high galanin mRNA expression correlated with poor disease-free
survival in early stage disease.
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MATERIALS AND METHODS
Materials
5-FU and Oxaliplatin were purchased from Sigma Chemical Co. (St. Louis, MO) and Abatra
Technology Co, LTD (China) respectively. zVAD (OMe)-FMK was purchased from
Calbiochem (Darmstadt, Germany). All siRNAs were purchased from Qiagen (Crawley,
UK).
Cell culture
Authentication and culture of CRC cell lines HCT116, LS174T, RKO, HT29, SW620 and
LoVo, has been described previously (15). LS174T (2008), SW620 (2008) and RKO (2001)
cells were obtained from the American Type Culture Collection (ATCC). The p53 wild-type
HCT116 human colon cancer cell line, kindly provided by Prof. Bert Vogelstein (Johns
Hopkins University, Baltimore, MD) in 2003. The 5-FU-, SN-38 and oxaliplatin-resistant
HCT116 sub-lines and the oxaliplatin-resistant p53 null HCT116 sub-line were generated in
our laboratory as previously described (16). The LoVo (2004) cells were obtained from the
European Collection of Cell Cultures (ECACC). RKO and HT-29 human cell lines were
provided by the National Cancer Institute. The 5-FU-and SN-38-resistant LoVo and HT29
sub-lines were generated in our laboratory by continuous exposure of increasing doses of
chemotherapy over an ~10 month period. The c-FLIPL overexpressing cell lines were
previously described (17).
Patient Samples
Eight patients with metastatic colorectal cancer were included in the present study. All
patients provided written fully informed consent as per IRB guidelines in the University of
Southern California and approval was granted from this body. Patients underwent biopsy of
colorectal liver metastases prior to commencing oxaliplatin/5-FU chemotherapy. CT
imaging for response evaluation using WHO criteria was performed every 6 weeks and
patients were subsequently designated as responders, stable disease or progressive disease.
Of these 8 patients, 1 had a partial response to treatment, 3 had stable disease and 4 had
progressive disease on treatment. For the purpose of this study we have further defined
‘responders’ as those patients with either partial response or stable disease and ‘non-
responders’ as those patients with progressive disease.
Microarray analysis
Total RNA was extracted from 8 pre-treatment metastatic tumour biopsies from patients
with advanced colorectal cancer and profiled on the Colorectal Disease Specific Array
(DSA™) Research Tool (Almac Diagnostics, Craigavon, UK). In addition, in vitro analyses
were also carried out using the Colorectal DSA™. The in vitro analyses have been
previously described for the 5-FU experiment (18) and the same experimental design was
used for the oxaliplatin experiment. Detailed experimental protocols and raw expression
data are available at ArrayExpress repository (19) (Accession number E-MEXP-3368
(Clinical analysis) and E-MEXP-1691 (in vitro analysis)).
Bioinformatic analysis
Generation of genelists—All data analysis was completed within Genespring v7.3.1
(Agilent Technologies, UK). All genelists were generated as previously described (6). The
filtering criteria used was (i) all data passing Affymetrix flag calls (P/M) in all samples were
retained, (ii) all data passing the cross gene error model with genes displaying control values
greater than the average base/proportional value being retained (this was required in all
samples for any gene), (iii) the list was filtered using a 1.5-fold cut-off for each gene relative
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to the control array and (iv) all data passing P<0.05 were retained. All data are displayed as
log2 transformed. For the in vitro analysis, the untreated parental samples were compared to
the drug-treated parental samples (inducible parental), the untreated drug-resistant samples
were compared to the drug treated drug-resistant samples (inducible resistant) and the
untreated parental cells were compared to the untreated drug-resistant cells (basally
deregulated), for both the 5-FU experiment and the oxaliplatin experiment. For the clinical
analysis a genelist was created of those genes that were altered between 5-FU/oxaliplatin
responding (PR+SD) and non-responding patients (PD). No patients achieved a complete
response (CR).
Pathway analysis—All pathway analysis was carried out using Genespring v7.3.1
(Agilent Technologies, UK) using both KEGG and GenMAPP pathways. Briefly, the final
working genelists for both the in vitro experiments and the clinical experiments were used as
the starting genelists and pathways were selected that contained greater than 5 genes per
pathway. Statistical analysis for each pathway was carried out using hypergeometric
statistics.
Gene Set Enrichment Analysis (GSEA)—GSEA is a computational method for
determining whether a rank-ordered list of genes for a particular comparison of interest is
enriched in genes derived from an independently generated gene set (20). GSEA was
performed with the expression dataset derived from the in vitro samples (inducible parental,
inducible resistant and constitutively altered) and then the clinical samples (responders v
non-responders). Gene sets from the Molecular Signatures Database (http://
www.broad.mit.edu/gsea/msigdb/index.jsp) were used for the enrichment study including
the curated gene sets from online pathway databases, publications in PubMed and
knowledge of domain experts (C2) and the gene ontology (GO) gene sets (C5). A false
discovery rate (FDR) below 25% was considered for significant enrichment.
RNAi Screening
This was performed using siRNAs targeting pre-selected genes identified from microarray
analysis. siRNA transfection conditions have been previously described (15). The drugs
used were 5-FU (IC30(48h)) and oxaliplatin (IC30(48h)). Cell viability was determined by
using a 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma) assay
as described previously (17). Combination index (CI) values were calculated as previously
described (21). The ToxiLight® BioAssay Kit was purchased from Lonza Rockland, Inc.
(Rockland, ME, USA) and was used according to the manufacturer’s instructions.
The RNAi screen comprised primary, secondary and tertiary screens. The primary screen
used single siRNAs targeting 84 candidate genes. Two-way ANOVA was used to classify
positive hits as targets which induced a significant increase (P<0.05) in relative toxicity (cell
death/cell viability), with either siRNA alone or siRNA combined with drug. This identified
30 positive hits which were carried forward to a secondary RNAi screen incorporating an
additional 3 siRNA sequences per target. Positive hits were classified by a significant
increase in relative toxicity with either siRNA alone or siRNA combined with drug for ≥2 of
the additional siRNA sequences. This identified 11 positive hits which were carried forward
to a tertiary RNAi screen. For each target, the optimum chemo-sensitizing siRNA from the
primary and secondary RNAi screens was used in a panel of 6 independent CRC cell lines.
siFGFR4_4 displayed particularly high levels of relative toxicity alone and was not
considered. A positive hit was classified as a significant increase in relative toxicity with
either siRNA alone or siRNA combined with drug in ≥3 CRC cell lines; this identified 6
positive hits.
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Q-PCR analysis
siRNA silencing of the candidate genes was confirmed by Q-PCR, as described previously
(15). Final expression values were normalised to GAPDH expression and presented relative
to the untreated time-matched siRNA control (SC).
Western blot analysis
Western blots were performed as previously described (22). Caspase 8 (12F5; Alexis) and
Poly-ADP-Ribose-Polymerase-1 (PARP; eBioscience, San Diego, CA) mouse monoclonal
antibodies were used in conjunction with a horseradish peroxidase-conjugated sheep anti-
mouse secondary antibody (Amersham, UK). Caspase 3 rabbit polyclonal antibody (Cell
Signaling Technology, Inc.) was used in conjunction with anti-rabbit secondary antibody
(Amersham, UK). GALR1 (Sigma) goat polyclonal antibody was used in conjunction with
donkey anti-goat secondary antibody (Santa Cruz). Equal loading was assessed using
GAPDH or actin (AbD Serotec, UK).
Annexin V/Propidium Iodide analysis
Cells were harvested and analysed according to the manufacturer’s instructions (BD
Biosciences, Oxford, UK). Annexin V/Propidium iodide (PI) analysis was carried out using
the EPICS XL Flow Cytometer (Coulter, Miami, FL, USA). Briefly, levels of apoptosis
were calculated as the sum of FITC-Annexin V positive/PI negative (early apoptosis) and
FITC-Annexin V positive/PI positive (late apoptosis) cell population.
Caspase Activation Assays
Caspase activity in cell protein isolates was measured using Caspase Glo 3/7, 8 and 9 assays
(Promega).
Analysis of public CRC datasets
Association of target gene expression with CRC tumour—Public CRC microarray
datasets were accessed (23) and CRC tumour expression data for Galanin mRNA was
downloaded (24, 25).
Association of target gene expression with clinical response—Public CRC
microarray datasets were accessed (26) and Galanin expression data sets GSE17536 (27)
and GSE14333 (28) were downloaded. GraphPad Prism 5 software was used to generate a
Kaplan-Meier survival curves for high and low expression groups. These were dichotomized
at the optimal cutpoint, as calculated by log-rank test (26).
RESULTS
Generation of in vitro- and clinically-derived genelists
An overview of our experimental approach is depicted in figure 1. Bioinformatic analysis of
the 5- FU in vitro data identified 1329 genes that were constitutively altered between the
parental and resistant cell lines (Table S1a), 1389 genes that were 5-FU inducible in parental
cells (Table S1b), and 922 genes that were 5-FU-inducible in 5-FU-resistant cells (Table
S1c). For oxaliplatin, 1164 genes were identified that were constitutively altered between
the parental and resistant cell lines (Table S1d), 643 genes that were oxaliplatin-inducible in
parental cells (Table S1e) and 373 genes that were oxaliplatin-inducible in oxaliplatin-
resistant cells (Table S1f). In the clinical samples, 939 genes were differentially expressed
when responding (PR+SD) and non-responding (PD) tumours were compared (Table S1g).
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Pathway Analysis
An overview of our bioinformatic analyses is outlined in figure 1. Pathways were selected
that contained >5 differentially expressed genes. This was applied to the clinical genelist,
and 3 in vitro gene lists: (i) genes inducible in the parental cell line (IP); (ii) genes
constitutively altered between parental and resistant cell lines (CA) and (iii) genes inducible
in the resistant cell line (IR), and this was carried out for both the 5-FU and oxaliplatin in
vitro data sets. Pathways that were found to be present in ≥4 genelists are listed in Table 1.
In the 5-FU experiment, 49 pathways were constitutively altered (Table S2a), 60 pathways
were 5-FU-inducible in parental cells (Table S2b) and 24 pathways were 5-FU-inducible in
5-FU-resistant cells (Table S2c). In the oxaliplatin in vitro experiment, 36 pathways were
constitutively altered (Table S2d), 16 pathways were oxaliplatin-inducible in parental cells
(Table S2e), and 11 pathways were oxaliplatin-inducible in oxaliplatin-resistant cells (Table
S2f). When pathway analysis was carried out on those genes altered between responding and
non-responding patients, a large number (n=42) of differentially regulated pathways were
identified (Table S2g). The most significant pathways identified in these analyses are
presented in Table 1; notably, these pathways overlap significantly with those identified in
the in vitro analyses.
Gene Set Enrichment Analysis (GSEA)
GSEA was carried out using the clinical responder versus non-responder genelist as the
molecular profile data with the C2 and C5 geneset databases. GSEA using the C2 geneset
database, which contains the functional sets, identified 48 genesets were significantly
enriched (false discovery rate (FDR) of <25%) in responding patients, while 2 genesets were
significantly enriched (FDR<25%) in non-responding patients (Table S3a). When the
analysis was carried out using the C5 geneset database, which contains the GO genesets, 171
genesets were significantly enriched (FDR<10%) in responding patients, while 10 genesets
were significantly enriched (FDR<10%) in non-responding patients (Table S3b). GSEA was
also carried out using the clinical responder versus non-responder genelist as the molecular
profile data with the oxaliplatin basally deregulated in vitro gene list as a user-defined
geneset. This identified a list of genes (n=508) that were enriched and up-regulated in both
oxaliplatin-resistant cells and non-responding patients (Table S3c).
Overlap between pathway analysis and GSEA
When the C2 and C5 GSEA results were compared to the pathway analysis results,
apoptosis, calcium signalling, cell cycle, cell communication, cytokine-cytokine receptor
interaction, focal adhesion/MAPK signalling, Gap junction, glycerophospholipid
metabolism, insulin signalling and regulation of actin cytoskeleton were found to
significantly correlate with the GSEA (Figure 1 and Table 1). From this list, we selected
apoptosis, cell cycle, focal adhesion, MAPK signalling and insulin signalling to study
further.
Candidate gene selection
Candidate genes (n=84) were chosen that passed a 1.5-fold change in expression with a P
value <0.05 within the identified pathways, and nodal points within these pathways were
prioritized (Table S4). Ligands such as the fibroblast growth factors were identified within
the MAPK signaling pathway, however, we opted to silence their receptors, to reduce the
number of candidate genes to be screened.
Primary RNAi screen
To identify genes which when down-regulated enhanced sensitivity to 5-FU/oxaliplatin, we
used the HCT116 cell line for the primary RNAi screen and single siRNAs against 84
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candidate genes. A positive hit was defined as a significant increase (P<0.05) in relative
toxicity (cell death/cell viability) with the targeting siRNA either alone or combined with
chemotherapy, and this was determined by 2-way-ANOVA. Thirty positive hits were
identified in the primary RNAi screen: 15 MAPK targets, 8 focal adhesion targets (Fig. 2A),
3 cell cycle targets, 2 insulin signalling targets, and 2 apoptosis targets (Fig. S1A). The
positive hits were carried forward to the secondary RNAi screen. A significant interaction
(P<0.05) between targeting siRNA and drug was observed for 11 of these genes (Table S5a).
Secondary RNAi screen
To validate the primary screen ‘hits’, 3 additional siRNAs per target were used, and
sensitizing effects were determined as before. Multiple siRNAs reproduced a sensitizing
phenotype for 11 of these targets: 6 MAPK targets (RAC2, RAPGEF2, FGFR4, MAPK9,
GALR1, and TFDP1), 2 focal adhesion targets (EMP2 and FLNB) (Fig. 2B), and 3 cell
cycle targets (CENPE, CDC20 and SMC4) (Fig. S1B). A significant chemotherapy
interaction was observed for siRNAs targeting RAC2, RAPGEF2, MAPK9 or GalR1 (Table
S5b). Gene silencing was confirmed by Q-PCR (Fig. S2A and B).
Tertiary RNAi screen
The focus of further validation was based on the MAPK/focal adhesion targets identified in
Fig. 2B. To rule out cell line-specific effects, a panel of 6 independent colorectal cancer cell
lines (HCT116, LS174T, RKO, SW620, LoVo and HT29) were incorporated into a tertiary
RNAi screen. The optimum chemo-sensitizing siRNA for each target from the previous
screens was used. Significant 5-FU/oxaliplatin sensitizing effects (P<0.05) were determined
as before. A sensitizing phenotype was observed across the cell line panel for 6 targets:
GalR1 (Fig. 2C), MAPK9, RAC2, FGFR4, EMP2 and TFDP1 (Fig. S1C). As a highly novel
and potentially druggable target, the GalR1/galanin receptor/ligand axis, was selected for
further functional analyses.
GalR1/galanin silencing synergistically enhances the effects of chemotherapy
HCT116 cells were transfected for 24h with GalR1 siRNA (siGALR1) or galanin siRNA
(siGAL) prior to a 24h/48h co-treatment with IC30(48h) doses of 5-FU/oxaliplatin. GalR1
silencing was confirmed by Western blot (Fig. 3A, inset) and galanin silencing was
confirmed by Q-PCR (Fig. 3B, inset). Cell viability was determined by MTT assay, and
combination index (CI) values were calculated (Fig. 3A). These analyses demonstrated that
siGALR1 was synergistic with 5-FU and oxaliplatin treatment, particularly at lower
concentrations of siRNA. Furthermore, synergy was also observed between siGAL and
chemotherapy treatment (Fig. 3B). Synergy was also demonstrated in the RKO and LS174T
cell lines following GalR1 silencing or galanin silencing (Fig. S3A and data not shown) and
the H630 cell line following galanin silencing (data not shown).
Drug resistant HCT116 models were also transfected for 24h with siGALR1 or siGAL prior
to 48h co-treatment with parental IC30(48h) and IC50(48h) doses of 5-FU/oxaliplatin. A
significant reduction in cell viability was observed following GalR1 or galanin silencing
alone in both the oxaliplatin-and 5-FU resistant HCT116 models, and this was further
reduced when combined with chemotherapy treatment (Fig. 3C). This reduction in viability
was synergistic for siGAL and oxaliplatin treatment. A similar interaction was observed in
the oxaliplatin-resistant HCT116 p53 null model (Fig. S3B). Silencing of galanin alone but
not GalR1, significantly reduced cell viability in other 5-FU-resistant models (LoVo and
HT29) (Fig. S3C). Of note, galanin/GalR1 silencing also significantly reduced cell viability
in models (HCT116, LoVo and HT29) resistant to the active metabolite of irinotecan, the
other chemotherapeutic agent currently approved for use in advanced CRC (Fig. S3D).
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These results indicate that drug resistant models maintain the dependency on galanin
signalling observed in the parental drug-sensitive cell lines.
GalR1/galanin silencing induces apoptosis in CRC cell lines
To determine the mechanism of chemo-sensitization following silencing of GalR1 and
galanin, HCT116 cells were transfected with 5nM siGALR1 or siGAL for 24h prior to a 24h
co-treatment with ~IC30(48h) doses of 5-FU or oxaliplatin; apoptosis levels were determined
by flow cytometry. GalR1 silencing for 48h resulted in significantly higher levels of
apoptosis (~47%) compared to ~10% in the control siRNA (SC) transfected cells (P<0.001)
(Fig. 3D). This was further enhanced to ~59% when combined with 5-FU and ~69% when
combined with oxaliplatin; 2-way ANOVA confirmed a significant interaction between
siGALR1 and 5-FU/oxaliplatin (P<0.001). Similar results were observed following galanin
silencing (Fig. 3D) and Western blot analysis demonstrated PARP cleavage (a hallmark of
apoptosis) following GalR1 silencing (Fig. 3D, inset), supporting the flow cytometry results.
This chemo-sensitizing phenotype was reproduced using a second siRNA sequence for both
GalR1 (siGALR1_1) and galanin (siGAL_5) (Fig. S4A). To assess whether the effects were
cell line-specific, LS174T and RKO CRC cell lines were analysed (Fig. S4B). In these
models, the effect of GalR1/galanin silencing on induction of apoptosis was less than in the
HCT116 cells. However, the sensitization to chemotherapy-induced apoptosis was still
observed in both these models and was again particularly marked for oxaliplatin. A
significant induction of apoptosis was observed following GalR1 or galanin silencing alone
in drug resistant models (Fig. S4C) and Western blot analysis demonstrated PARP cleavage
and activation of the executioner caspase, caspase 3 following GalR1/galanin silencing,
further supporting the flow cytometry results (Fig. S4D).
GalR1/galanin silencing down-regulates FLIPL and activates caspase 8-dependent
apoptosis
Caspase-dependent apoptosis following GALR1 silencing was confirmed using the pan-
caspase inhibitor, zVAD, which completely attenuated apoptosis (Fig. 4A). Analysis of
caspase activity following GalR1 silencing indicated that there was a close correlation
between the activity of the executioner caspases 3 and 7 and the initiator caspase, caspase 8
(Pearson’s correlation coefficient of r=0.99), suggesting a role for caspase 8 in initiation of
the apoptotic phenotype (Fig. 4B). To investigate this further, HCT116 cells were co-
transfected with siGALR1 and siCaspase 8 for 48h. Notably, co-silencing of caspase 8
resulted in inhibition of siGALR1- induced apoptosis (Fig. 4C). Western blot analysis
demonstrated that GalR1 silencing induced PARP cleavage and processing of procaspase 8
and that PARP cleavage was blocked by co-silencing of caspase 8 (Fig. 4C, inset).
Similarly, the apoptosis induced by galanin silencing (Fig. 4C and S5A) was blocked by co-
transfection with siCaspase 8 (Fig. 4C).
Given the caspase 8-dependent manner of siGALR1/siGAL-induced apoptosis, the
expression of FLIPL, an endogenous inhibitor of caspase 8 activation, was investigated.
FLIPL levels were found to be down-regulated following transfection with siGALR1 (Fig.
4C, inset and S5B) or siGAL (Fig. S5A). FLIPL down-regulation was confirmed with 2
additional siRNA sequences (29) (siGALR1_1 and siGALR1_4) (Fig. S5C) and an
additional CRC cell line (RKO) (Fig. S5D). Moreover, a FLIPL overexpressing cell line
FL17 (17) was significantly resistant to apoptosis induction following GalR1/galanin
silencing compared to the parental HCT116 cell line (P<0.01, Fig. 4D). These results
indicate for the first time that FLIPL is a key downstream effector of GalR1/galanin-
mediated anti-apoptotic signalling.
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Clinical Relevance of Galanin expression in CRC
Using publicly available data sets, galanin mRNA expression was found to be significantly
up-regulated in CRC tumours compared to normal colon from 2 independent studies: a 1.7-
fold increase; P=3.2E-5 (Fig. 5A;(23, 24)) and a 1.9-fold increase; P=2.59E-8 (Fig. 5B, (23,
25)). Having identified galanin and its receptor as determinants of chemotherapy resistance,
we examined whether galanin mRNA expression was a potentially useful clinical biomarker
in CRC. Using the oxaliplatin constitutively altered (CA) genelist (Table S1d), GSEA
identified genes that were enriched and up-regulated in non-responding patients
(FDR<25%). Galanin was identified in the top 24 genes that were significantly up-regulated
(P<0.05) and enriched in both the oxaliplatin-resistant cells and non-responding patients
(Table S3C). We then examined the prognostic value of galanin mRNA expression, since
predictive biomarkers may also have prognostic value. Importantly, analysis of galanin
mRNA expression in the early stage patients within the GSE17536 CRC dataset (27)
revealed a significant correlation between high galanin expression and decreased disease-
free survival (DFS) (Fig. 5C; P=0.0077; n=135). Notably, when the early stage patient
cohort was broken down into individual stages, this correlation was lost in the stage III
cohort, but remained highly significant in the stage I and stage II cohorts (Figure 5C,
P=0.0036 and P=0.0025 respectively). In a separate CRC dataset (GSE14333) (28), a
significant correlation between high galanin mRNA expression and poorer disease-free
survival was also observed in the Dukes stage B (stage II) patients (Fig. 5D, P=0.03). Non-
significant trends were observed between high galanin mRNA expression and poorer DFS in
Dukes A disease (stage I, P=0.06) and when stages A, B and C were combined (P=0.098).
This data suggests a potential association between high galanin mRNA expression and poor
patient outcome in early stage CRC. There were insufficient numbers of clinical samples
within these public data sets to explore the potential of galanin as a predictive biomarker;
ongoing studies aim to further examine the clinical relevance of galanin mRNA expression
as both a predictive and prognostic factor.
DISCUSSION
Resistance to chemotherapy remains a major problem in CRC, both in the adjuvant and
advanced disease settings. In this study, we used a systems biology approach comprising
both in vitro and clinical microarray data to identify novel genes and pathways that regulate
5- FU/oxaliplatin resistance together with a functional genetic approach to identify chemo-
sensitizing interactions between specific proteins and chemotherapy in CRC cells. Pathway
analysis and GSEA identified MAPK signalling, insulin signalling, cell cycle, focal
adhesion and apoptosis as key determinants of drug sensitivity. Using an siRNA screening
approach, we examined whether down-regulating specific nodal points within these
pathways enhanced 5- FU/oxaliplatin sensitivity. From the chemo-sensitizing targets
identified in our study, GalR1 was considered to be highly novel and was prioritized for
further functional analysis.
GalR1 is one of 3 galanin receptors and is the predominantly expressed galanin receptor in
the human colon (30). The galanin receptor ligands are neuropeptides and include galanin
(GAL), galanin-message-associated peptide (GMAP), a derivative from the same peptide
precursor as galanin, galanin-like peptide (GALP), which is encoded by a different gene,
and alarin, which is encoded by a splice variant of the GALP gene. Galanin’s functions in
the GI tract include inhibition of gastric acid secretion and inhibition of the release of
pancreatic peptides such as insulin, amylase, glucagon and somatostatin. This study focused
on GalR1 and the ligand, galanin, as to date, no specific GI-tract functions have been
delineated for GalR2, GalR3 or the ligands GMAP, GALP or alarin (30).
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There are many reports of cancer-promoting properties for GalR1. It is known to signal
through the MAPK pathway, and mitogenic effects of galanin have been reported in
pancreatic cancer cells (31), small cell lung cancer cells (32) and rat pituitary tumour cells in
vitro (33). Galanin has also been found to be up-regulated in the serum of CRC patients
compared to healthy donors (34), and CGH analyses showed gains at the galanin locus,
11q13, in CRC metastases (35), which has been associated with poor outcome (36). In
contrast, GalR1 has been implicated as a tumour suppressor since loss of the GALR1 locus,
18q23, have been reported in HNSCC (37) and metastatic CRC tumours (30, 38). In
addition, galanin stimulation of GalR1 overexpressing oral SCCs was shown to induce ERK
activation, and this was associated with suppressed cell proliferation, inhibition of colony
formation and suppressed tumour growth in vivo (39). It has been suggested that the
different signal transduction pathways associated with each galanin receptor may account
for distinct biological activities of galanin in different types and possibly different stages of
cancer (30). Therefore the impact of galanin signalling may depend on the expression level
of each receptor, which in turn may vary in a tissue-and tumour-specific manner.
Galanin is considered to be a marker of pluripotent stem cells. Four of the most significantly
over-expressed genes in undifferentiated embryonic tissue are galanin, POU5F1 (Oct3),
NANOG and DPPA4 (10, 12) with galanin highlighted as the most abundantly expressed in
human and rodent embryonic stem cells (ESCs) (10, 14). Furthermore, a 92 gene molecular
signature of “stemness” in 6 human ESC lines found that galanin mRNA was the most
abundant transcript, along with those of Pou5F1, Nanog, Sox2 and FoxD3 (9, 10). Up-
regulation of galanin mRNA and protein expression has been reported in undifferentiated
embryonal carcinoma, suggesting it may be a diagnostic marker for undifferentiated tumour
cells (40). Cancer cells possessing stem-cell properties have been described in solid
tumours, and it is hypothesised that tumour cells with stem-cell attributes are chemo-
refractory (41, 42). It is possible therefore that galanin’s potential role in maintaining stem
cell-like properties is linked to the novel role we have identified for this ligand in mediating
chemotherapy resistance in CRC. Further work is ongoing to explore this possibility.
Analysis of our microarray data sets using a customised GSEA found that high galanin
mRNA expression was enriched in the oxaliplatin-resistant setting in vitro and in non-
responding patients. Further investigation of galanin mRNA expression in public data-sets
revealed that galanin was over-expressed in colorectal tumours compared to normal colon.
Importantly, high galanin expression was also significantly associated with poorer DFS of
CRC patients, specifically in early stage disease. The clinical management of stage II CRC
is a matter of debate as the majority of patients are cured by surgery alone (43). The
identification of the ~15-20% of stage II CRC patients who are most likely to relapse is
therefore highly clinically relevant as these patients could be selected for treatment with
adjuvant chemotherapy, whereas the patients who are unlikely to relapse could be spared the
toxic side-effects of chemotherapy treatment. A number of studies, including one involving
our group, have attempted to identify prognostic biomarkers for stage II CRC (44-46). The
preliminary data presented in this study suggest that galanin mRNA expression may be a
useful prognostic biomarker for stage II disease; this is currently being examined in larger
patient cohorts.
Previous findings by our group have identified FLIP, in particular FLIPL as a key
determinant of drug resistance in CRC (3). The mechanism by which GalR1 silencing
enhanced chemo-sensitivity in CRC was shown to involve caspase 8-dependent apoptosis
following down-regulation of FLIPL. This is the first demonstration of a link between FLIP
and galanin/GalR1; the mechanistic basis by which GalR1/galanin regulates the expression
of FLIP and other downstream apoptosis-regulating proteins is the subject of ongoing
studies. We previously found that high FLIP expression was an independent prognostic
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factor in stage II/III CRC (47). Given the prognostic significance of galanin expression and
its role as an upstream regulator of FLIP expression, it is possible that high galanin levels
promote high FLIP expression in CRC tissues resulting in a more aggressive disease
phenotype. This would implicate the galanin signalling pathway as a potentially important
therapeutic target in CRC.
In summary, using a systems biology approach, we have identified several pathways as
potential mediators of 5-FU/oxaliplatin response and resistance. From these analyses, we
identified GalR1/galanin as a novel receptor-ligand system that regulates CRC cell survival
and drug resistance. The mechanism by which GalR1/galanin mediates 5-FU/oxaliplatin
resistance in CRC was found to be due (at least in part) to its upstream regulation of FLIPL
expression. Notably, galanin mRNA expression was found to be up-regulated in colorectal
tumour versus normal tissue and overexpressed and enriched in the non-responding patients
of this study. Moreover, high galanin mRNA levels also correlated with a poorer prognosis
in CRC patient cohorts, particularly in stage II disease. Together, these findings provide the
foundation for further research into GalR1/galanin as a novel therapeutic target and/or
prognostic biomarker in CRC.
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STATEMENT OF CLINICAL RELEVANCE
Chemotherapy resistance is a major factor limiting effective clinical management of
colorectal cancer (CRC). Therefore, the identification of therapeutically targetable
mediators of resistance is vital. The aim of this study was to identify potentially
druggable targets using a sytems biology approach. This resulted in the identification of
the receptor-ligand axis, G-protein coupled receptor galanin receptor 1 (GalR1) and
galanin as a novel regulator of drug resistance. Silencing GalR1 or its ligand galanin
induced apoptosis in drug-sensitive and drug-resistant cells and synergistically enhanced
chemotherapy. Galanin was overexpressed in colorectal tumours and high galanin
expression correlated with poor disease-free survival of early stage CRC patients.
Collectively, these results demonstrate a novel role for GalR1/galanin in chemo-
resistance, providing evidence to support its further evaluation as a potential therapeutic
target and biomarker in CRC.
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Fig. 1. Experimental overview
Schematic of the systems biology approach used to identify novel determinants of resistance
to 5-FU and oxaliplatin in CRC. Microarray profiling was carried out on sensitive and
resistant in vitro models and clinical samples from responding and non responding patients.
Genelists generated from the microarray data were analysed by pathway analysis and gene
set enrichment analysis to identify key pathways mediating resistance to 5-FU and
oxaliplatin. Candidate genes from the selected pathways were functionally assessed by
RNAi screening. CA=constitutively altered, IP=inducible parental, IR=inducible resistant,
FDR=false discovery rate.
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Fig. 2. Positive hits from RNAi screening
(A) The primary RNAi screen was carried out in the HCT116 cell line with 1 siRNA
sequence per target to functionally assess 84 candidate genes from key pathways. A positive
‘hit’ was defined by 2-way ANOVA as a significant (P<0.05) increase in relative toxicity
(cell death/cell viability) with siRNA alone or siRNA combined with drug. (B) A secondary
RNAi screen used an additional 3 siRNA sequences per target. A positive hit was classified
as a significant increase in relative toxicity alone or combined with drug with ≥2 additional
siRNA sequences. (C) A tertiary RNAi screen used the optimum chemo-sensitizing siRNA
from the previous screens and incorporated a panel of 6 independent CRC cell lines. A
positive hit was classified as a significant increase in relative toxicity alone or combined
with drug in ≥3 cell lines. Results are given as mean values ± SEM of triplicate
measurements. *P<0.05; **P<0.01; ***P<0.001. SC=siRNA control; si=targeted siRNA;
SOL=solvent control.
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Fig. 3. Galanin/GalR1 silencing is synergistic with chemotherapy treatment
Cell viability assays were conducted in the HCT116 parental cell line and the method of
Chou and Talalay was used to evaluate the interaction between (A) GalR1 siRNA
(siGALR1) or (B) galanin siRNA (siGAL) and increasing concentrations of either 5-FU or
oxaliplatin at 48/72h. CI values <1, =1, and >1 indicating synergism, additivity, and
antagonism, respectively. GALR1 silencing was confirmed by Western blot (A, inset) and
galanin silencing was confirmed by Q-PCR (B, inset). (C) Cell viability of HCT116
oxaliplatin-resistant (OXR) and 5-FU-resistant (FUR) cell lines following galanin/GalR1
silencing (10nM siRNA) for 24h prior to 48h co-treatment with parental IC30(48h) and
IC50(48h) doses of chemotherapy. A synergistic interaction was determined by 2-way
ANOVA. *P<0.05; ***P<0.001 (D) Annexin V/PI flow cytometric analysis was used to
measure apoptosis levels in HCT116 parental cells following galanin/GalR1 silencing (5nM
siRNA) for 24h prior to a 24h co-treatment with IC30(48h) doses of either 5-FU or
oxaliplatin. (D, inset) Western blot showing PARP cleavage in HCT116 cells transfected
with 5nM siGALR1 for 24h prior to a 24h co-treatment with ~IC30(48h) doses of either 5-FU
or oxaliplatin. Results are given as mean values ± SEM of triplicate measurements. *P<0.05;
**P<0.01; ***P<0.001. SC=siRNA control.
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Fig. 4. Galanin/GalR1 silencing induces caspase 8-dependent apoptotic cell death
Annexin V/PI flow cytometric analysis was used to measure apoptosis levels. (A) HCT116
cells were transfected with 5nM siGALR1 ± 10μM zVAD for 24h prior to a 24h co-
treatment with IC30(48h) doses of either 5-FU or oxaliplatin. (B) Caspase 3/7 and 8 activity
levels in HCT116 cells following 24h GalR1 silencing (5nM siRNA) prior to a 24h co-
treatment with IC30(48h) doses of either 5-FU or oxaliplatin. (C) HCT116 cells following 48h
GalR1/galanin (5nM siRNA) and Caspase 8 (10nM siRNA) co-silencing. (C, inset) Western
blotting was used to measure expression of PARP, caspase 8 and FLIPL following 24h
GalR1 and Caspase 8 co-silencing. (D) HCT116 parental cells and the FLIPL overexpressing
cell line, FL17, following 24h GalR1/galanin silencing (5nM siRNA). Results are mean
values ± SEM of triplicate measurements. *P<0.05; **P<0.01; ***P<0.001. SC=siRNA
control.
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Fig. 5. Clinical Galanin expression data
(A and B) Public data sets of galanin mRNA expression in CRC tumour (T) compared to
Normal (N). Kaplan-Meier analysis, using the Log-rank (Mantel-Cox) statistical test, of (C)
CRC GSE17536 dataset (probe ID: 214240_at) revealed that high galanin expression
significantly correlated with decreased disease-free survival in stages I, II and III patients
combined (HR=0.2143; 95% CI of ratio=0.06918 to 0.6641; P=0.0077; n=135), stage I only
patients (P=0.0036) and stage II only patients (P=0.0025) but not stage III patients (NS) and
(D) CRC GSE14333 dataset (probe ID: 214240_at) revealed a trend for high galanin and
decreased disease-free survival in combined stages (P=0.098; n=246) and Duke’s A patients
(P=0.06). There was a significant correlation between high galanin expression and decreased
disease free survival in the Duke’s B patients (P=0.03).
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